Swiss Drug Delivery Specialist SHL Medical Expands Global Footprint with New $220M Autoinjector Facility in South Carolina

SHL Medical, a leading drug delivery specialist based in Switzerland, has officially opened its new state-of-the-art autoinjector production facility in North Charleston, South Carolina. The $220 million investment marks a significant expansion of the company's global manufacturing capabilities and reinforces its position as a frontrunner in providing end-to-end drug delivery solutions.

Cutting-Edge Facility Boosts U.S. Presence

The newly inaugurated 360,000-square-foot plant is set to produce autoinjectors for a range of therapeutic areas, including endocrine and metabolic disorders, as well as musculoskeletal diseases. Featuring fully automated production lines and the latest in medical device injection molding technology, the facility is expected to create 300 jobs in the region.

Ulrich Faessler, SHL's CEO and chairman, emphasized the strategic importance of the new plant, stating, "U.S.-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions." Faessler also highlighted the company's unique positioning, adding, "With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers."

Global Expansion and Production Capabilities

The South Carolina facility complements SHL's existing assembly, labeling, and packaging operations in Deerfield Beach, Florida, further strengthening the company's presence in the United States. This expansion is part of a broader growth strategy that has attracted significant financial backing from a consortium of investors, including Stockholm-based EQT, ATHOS, and other co-investors.

SHL's ambitious plans are reflected in its production targets, with the company expecting to deliver an impressive 1.5 billion devices to customers this year. This substantial output underscores the growing demand for advanced drug delivery systems and SHL's capacity to meet these needs on a global scale.